Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cancer Treatment Reviews

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ctrv.2017.10.008PMID 29126017
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer

  2014cited by this paper
• Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma

  2014cited by this paper
• Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications

  2014cited by this paper
• Emerging EGFR antagonists for breast cancer

  2014cited by this paper
• Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes

  2014cited by this paper
• Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients

  2014cited by this paper
• EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial

  2014cited by this paper
• Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer

  2014cited by this paper
• High EGFR gene copy number predicts poor outcome in triple-negative breast cancer

  2014cited by this paper
• Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.

  2014cited by this paper
• Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.

  2013cited by this paper
• Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts

  2013cited by this paper
• EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray

  2012cited by this paper
• Association of ErbB1–4 expression in invasive breast cancer with clinicopathological characteristics and prognosis

  2012cited by this paper
• Targeted therapy for triple‐negative breast cancer: Where are we?

  2012cited by this paper
• EGFR overexpression relates to triple negative profile and poor prognosis in breast cancer patients in Tunisia

  2012cited by this paper
• Role of epidermal growth factor receptor in breast cancer

  2012cited by this paper
• The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy

  2012cited by this paper
• Triple‐negative breast cancer in Hispanic patients

  2011cited by this paper
• Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

  2011cited by this paper
• Adjuvant trastuzumab in HER2-positive breast cancer.

  2011cited by this paper
• Significance of epidermal growth factor receptor expression in breast cancer

  2011cited by this paper
• Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis

  2010cited by this paper
• Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes

  2010cited by this paper
• Molecular Mechanism and Clinical Implications of Endocrine Therapy Resistance in Breast Cancer

  2010cited by this paper
• A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy.

  2009cited by this paper
• EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.

  2009cited by this paper
• Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity

  2009cited by this paper
• Independent prognostic value of the basal‐like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI‐1

  2008cited by this paper
• Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study

  2008cited by this paper
• Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas

  2008cited by this paper
• Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study

  2008cited by this paper
• Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome.

  2008cited by this paper
• Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.

  2008cited by this paper
• Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer

  2008cited by this paper
• Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients

  2008cited by this paper
• Evaluation of the Prognostic and Predictive Value of HER-1/EGFR in Breast Cancer Patients Participating in a Randomized Study with Dose-Dense Sequential Adjuvant Chemotherapy

  2008cited by this paper
• A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.

  2007cited by this paper
• Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.

  2007cited by this paper
• Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer.

  2007cited by this paper
• Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast.

  2007cited by this paper
• EGFR gene and protein expression in breast cancers.

  2007cited by this paper
• Prognostic markers in triple‐negative breast cancer

  2007cited by this paper
• ErbB‐receptors expression and survival in breast carcinoma: A 15‐year follow‐up study

  2006cited by this paper
• Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin‐based neoadjuvant chemotherapy

  2005cited by this paper
• Prognostic value of epidermal growth factor expression in breast cancer

  2005cited by this paper
• The prognostic significance of epidermal growth factor receptor expression in breast cancer

  2005cited by this paper
• Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.

  2005cited by this paper
• Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer?

  2005cited by this paper
• Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay — a retrospective study

  2004cited by this paper
• Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study

  2004cited by this paper
• Determination of epidermal growth factor receptor provides additional prognostic information to measuring tumor angiogenesis in breast carcinoma patients

  2004cited by this paper
• A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma

  2004cited by this paper
• The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients

  2004cited by this paper
• Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer

  2004cited by this paper
• The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study

  2004cited by this paper
• Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer

  2004cited by this paper
• Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer

  2004cited by this paper
• HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer

  2004cited by this paper
• Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.

  2003cited by this paper
• HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors.

  2002cited by this paper
• Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.

  2001cited by this paper
• The ErbB signaling network: receptor heterodimerization in development and cancer

  2000cited by this paper
• Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.

  2000cited by this paper
• Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer

  1996cited by this paper
• Immunohistochemical detection of epidermal growth factor receptor lacks prognostic significance for breast carcinoma.

  1995cited by this paper
• Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: double-differential polymerase chain reaction (ddPCR) for clinical diagnosis.

  1995cited by this paper
• The prognostic value of epidermal growth factor receptor (EGFR) in breast cancer patients. Results of a follow-up study on 149 patients.

  1994cited by this paper
• Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity.

  1993cited by this paper
• The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients.

  1992cited by this paper
• Synthetic oligonucleotides as therapeutic agents.

  1991cited by this paper
• Prognostic value of epidermal growth factor receptor in node-positive breast cancer

  1989cited by this paper
• Structure and expression of c‐erbB‐2 and EGF receptor genes in inflammatory and non‐inflammatory breast cancer: Prognostic significance

  1989cited by this paper
• Epidermal growth factor receptors

  1981cited by this paper
• Access to the Published Version May Require Journal Subscription. Published with Permission From: Springer Epidermal Growth Factor Receptor (egfr) and the Estrogen Receptor Modulator Amplified in Breast Cancer (aib1) for Predicting Clinical Outcome after Adjuvant Tamoxifen in Breast Cancer

  year unknowncited by this paper

• OTUD4 deubiquitination stabilizes EGFR and activates the PI3K/AKT pathway to promote the invasiveness of triple-negative breast cancer.

  2026cites this paper
• Targeting Oncogenic Pathways in Multiple Cancers Using Isolated Bioactive Compounds from Bergenia ciliata: A Network Pharmacology, Molecular Docking, Molecular Dynamics and in vitro Study

  2026cites this paper
• Hallmarks of cancer in canine mammary tumors: Insights into a potential model for human triple-negative breast cancer.

  2026cites this paper
• Targeting the tumor microenvironment in triple-negative breast cancer: Biological insights and therapeutic opportunities.

  2025cites this paper
• The m6A demethylase FTO suppresses glioma proliferation by regulating the EREG/PI3K/Akt signaling pathway

  2025cites this paper
• Multi-omics profile of exceptional long-term survivors of AJCC stage III triple-negative breast cancer.

  2025cites this paper
• Breast cancer exosomes: Managing macrophage polarization and immune regulation in the tumor microenvironment.

  2025cites this paper
• Recent research and uses of asparagus racemosus (Shatavari)

  2025cites this paper
• Decoding molecular signatures and identifying therapeutic targets in triple-negative breast cancer subtypes using omics and network analysis

  2025cites this paper
• An Interpretable Machine Learning Model for Predicting 5‐Year Survival in Breast Cancer Based on Integration of Proteomics and Clinical Data

  2025cites this paper
• Activation of epidermal growth factor receptors in triple-negative breast cancer cells by morphine; analysis through Raman spectroscopy and machine learning.

  2024cites this paper
• Comprehensive review of drug resistance in mammalian cancer stem cells: implications for cancer therapy

  2024cites this paper
• EGFR and MUC1 as dual-TAA drug targets for lung cancer and colorectal cancer

  2024cites this paper
• Global biomarker trends in triple-negative breast cancer research: a bibliometric analysis

  2024cites this paper
• Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy

  2024cites this paper
• Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins

  2023cites this paper
• Recent advances in peptide-based therapeutic strategies for breast cancer treatment

  2023cites this paper
• Incidental detection of ground glass nodules and primary lung cancer in patients with breast cancer: prevalence and long-term follow-up on chest computed tomography

  2023cites this paper
• Identification of 3‐(5‐cyano‐6‐oxo‐pyridin‐2‐yl)benzenesulfonamides as novel anticancer agents endowed with EGFR inhibitory activity

  2023cites this paper
• Quercetin-loaded Liposomes Effectively Induced Apoptosis and Decreased the Epidermal Growth Factor Receptor Expression in Colorectal Cancer Cells: An In Vitro Study

  2023cites this paper
• HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel

  2023cites this paper
• Cytotoxic activity of quinolinequinones in cancer: In vitro studies, molecular docking, and ADME/PK profiling

  2023cites this paper
• Dysregulated Signalling Pathways Driving Anticancer Drug Resistance

  2023cites this paper
• Predictive multigenic scale. Analysis of own results in metastatic breast cancer

  2023cites this paper
• An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma

  2023cites this paper
• Elucidating the molecular targets of Curcuma longa for breast cancer treatment using network pharmacology, molecular docking and molecular dynamics simulation

  2023cites this paper
• CircEGFR reduces the sensitivity of pirarubicin and regulates the malignant progression of triple-negative breast cancer via the miR-1299/EGFR axis.

  2023cites this paper
• Simultaneous Detection of Tumor Derived Exosomal Protein-MicroRNA Pairs with an Exo-PROS Biosensor for Cancer Diagnosis.

  2023cites this paper
• Surface roughness modulates EGFR signaling and stemness of triple-negative breast cancer cells

  2023cites this paper
• Prognostic and Predictive Biomarkers in Familial Breast Cancer

  2023cites this paper
• Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer

  2023cites this paper
• Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer

  2022cites this paper
• Kinome-Wide Profiling Identifies Human WNK3 as a Target of Cajanin Stilbene Acid from Cajanus cajan (L.) Millsp.

  2022cites this paper
• Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody (134-mG2a-f) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma

  2022cites this paper
• Mammaglobin, GATA-binding protein 3 (GATA3), and epithelial growth factor receptor (EGFR) expression in different breast cancer subtypes and their clinical significance

  2022cites this paper
• Antitumor Activities in Mouse Xenograft Models of Canine Mammary Gland Tumor by Defucosylated Mouse-Dog Chimeric Anti-Epidermal Growth Factor Receptor Antibody (E134Bf)

  2022cites this paper
• The dynamic, motile and deformative properties of RNA nanoparticles facilitate the third milestone of drug development.

  2022cites this paper
• Recent Advances in Nanotechnology-Based Targeted Therapeutics for Breast Cancer Management.

  2022cites this paper
• Magnetic Resonance Imaging Features in Diagnosis of Breast Cancer and Evaluation of Effect of Epidermal Growth Factor Receptor-Targeted Therapy

  2022cites this paper
• Expression of ERBB gene family in females with breast cancer and its correlation with clinicopathological characteristics of the disease

  2022influential citation
• Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker

  2022cites this paper
• The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells

  2022cites this paper
• Cysteine Cathepsins in Breast Cancer: Promising Targets for Fluorescence-Guided Surgery

  2022cites this paper
• Immune-related gene risk score predicting the effect of immunotherapy and prognosis in bladder cancer patients

  2022cites this paper
• Transcriptomics and Proteomics Characterizing the Anticancer Mechanisms of Natural Rebeccamycin Analog Loonamycin in Breast Cancer Cells

  2022cites this paper
• Nutraceutical and Dietary Resources for Breast Cancer Prevention – Highlighting Strategies for Suppressing Breast Aromatase Expression

  2022cites this paper
• ‘Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research’

  2022cites this paper
• Development and Validation of the ELISA Method for Anti-trastuzumab Antibodies Determination in Human Serum

  2022cites this paper
• The role of pro- and antiangiogenic factors in angiogenesis process by Raman spectroscopy

  2021cites this paper
• Recent advances in understanding the molecular role of phosphoinositide-specific phospholipase C gamma 1 as an emerging onco-driver and novel therapeutic target in human carcinogenesis.

  2021cites this paper
• Defucosylated Mouse–Dog Chimeric Anti-EGFR Antibody Exerts Antitumor Activities in Mouse Xenograft Models of Canine Tumors

  2021cites this paper
• Carboxylated chitosan-mediated improved efficacy of mesoporous silica nanoparticle-based targeted drug delivery system for breast cancer therapy.

  2021cites this paper
• Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review

  2021cites this paper
• GABRP sustains the stemness of triple-negative breast cancer cells through EGFR signaling.

  2021cites this paper
• Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer

  2021cites this paper
• Polymorphisms in EGFR Gene Predict Clinical Outcome in Unresectable Non-Small Cell Lung Cancer Treated with Radiotherapy and Platinum-Based Chemoradiotherapy

  2021cites this paper
• Epigenetic changes with age primes mammary luminal epithelia for cancer initiation

  2021cites this paper
• Bisphosphonates and risk of cancers: a systematic review and meta-analysis

  2020cites this paper
• Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers

  2020cites this paper
• Prognostic significance of EGFR, MUC1 and PD-L1 expressions in cases with triple negative breast cancer.

  2020cites this paper
• Expression of estrogen receptor α variants and c-Fos in rat mammary gland and tumors.

  2020cites this paper
• immunOhistOchemical markers intO screening methOds fOr BRCA 1-mutated breast cancer

  2020cites this paper
• EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer

  2020cites this paper
• Targeted Therapies for Breast Cancer Brain Metastases.

  2020cites this paper
• Triple-negative breast cancer: promising prognostic biomarkers currently in development

  2020cites this paper
• Oncogenic allelic interaction in Xiphophorus highlights hybrid incompatibility

  2020cites this paper
• Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery

  2020cites this paper
• Prognostic impact of serum levels of EGFR and EGFR ligands in early-stage breast cancer

  2020cites this paper
• Plasma C-MYC level manifesting as an indicator in progression of breast cancer.

  2019cites this paper
• MAT2B promotes proliferation and inhibits apoptosis in osteosarcoma by targeting epidermal growth factor receptor and proliferating cell nuclear antigen

  2019cites this paper
• Development of bioactive gemcitabine-D-Lys6-GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile.

  2019cites this paper
• 3D in vitro models of tumors expressing EGFR family receptors: a potent tool for studying receptor biology and targeted drug development.

  2019cites this paper
• Impedimetric label-free detection of salivary EGFR on screen printed electrode

  2019cites this paper
• Prognostic value of ephrin B receptors in breast cancer: An online survival analysis using the microarray data of 3,554 patients

  2019cites this paper
• β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer

  2019cites this paper
• Impact of endocrine disruptor hexachlorobenzene on the mammary gland and breast cancer: The story thus far.

  2019cites this paper
• Salivary Protein Antigens for Breast Cancer Biomarkers

  2019cites this paper
• Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples

  2019cites this paper
• PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.

  2019cites this paper
• Biological rationale for a patient-specific approach in the treatment of breast cancer. Clinical value of novel biomarkers of breast cancer

  2019cites this paper
• EGF receptor stimulation shifts breast cancer cell glucose metabolism toward glycolytic flux through PI3 kinase signaling

  2019cites this paper
• Rethink of EGFR in Cancer With Its Kinase Independent Function on Board

  2019cites this paper
• The trip of a drug inside the body: From a lipid-based nanocarrier to a target cell.

  2019cites this paper
• Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer.

  2018cites this paper
• Profiling plasma extracellular vesicle by pluronic block-copolymer based enrichment method unveils features associated with breast cancer aggression, metastasis and invasion

  2018cites this paper
• The inhibitory effects of COL1A2 on colorectal cancer cell proliferation, migration, and invasion

  2018cites this paper